C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma
PLOS One · 07.05.2025 · 20 (5) · e0322701
DOI: 10.1371/journal.pone.0322701 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 07.05.2025. Verfasst von Xiang-Rong Yao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSC) is a prevalent and aggressive malignancy with poor prognosis, underscoring the need for novel biomarkers and therapeutic strategies. This study investigates the role of C16orf74 as a potential diagnostic and prognostic biomarker in HNSC. Bioinformatics analyses revealed that C16orf74 is significantly overexpressed in HNSC and is associated with advanced disease stages, therapy resistance, and shorter overall and progression-free survival. A prognostic nomogram integrating C16orf74 expression with clinicopathological features demonstrated robust predictive performance. Functional enrichment and immune infiltration analyses suggest that high C16orf74 expression might contribute to an immunosuppressive tumor microenvironment by reducing key immune cell populations, such as B cells, T cells, and natural killer cells, which are critical for anti-tumor immunity. Moreover, C16orf74 expression was inversely associated with immune checkpoint expression and immunotherapy response, highlighting its potential as a predictive biomarker for immune checkpoint blockade (ICB) efficacy. Drug sensitivity analyses identified potential therapeutic agents, including arsenic trioxide, carmustine, vincristine, quercetin, and carboplatin for patients with high C16orf74 expression. These findings highlight the potential of C16orf74 as a biomarker and therapeutic target to improve HNSC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
- School of Public Health, University of South China, Hengyang, China.
- Department of Radiation Oncology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong University, Nantong, China.
- Department of Pathology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
ORCID-Profile: Jun-Yan He
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Yao, X. R., Xiao, F. Z., Xiao, W. T., Huang, C. Q., & He, J. Y. (2025). C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma. PLOS One, 20(5), e0322701. https://doi.org/10.1371/journal.pone.0322701
Vancouver
Yao XR, Xiao FZ, Xiao WT, Huang CQ, He JY. C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma. PLOS One. 2025;20(5):e0322701. doi:10.1371/journal.pone.0322701
BibTeX
@article{Yao2025,
author = {Yao, Xiang-Rong and Xiao, Fang-Zhu and Xiao, Wen-Tao and Huang, Cui-Qin and He, Jun-Yan},
title = {C16orf74 is a novel prognostic biomarker and associates with immune infiltration in head and neck squamous cell carcinoma},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {5},
pages = {e0322701},
doi = {10.1371/journal.pone.0322701}
}
EUVIMED